Genprex, Inc. filed a Form 8-K on November 4, 2026, announcing that new research identifying TROP2 expression as a potential predictive biomarker of response to its lead drug candidate, Reqorsa (quaratusugene ozeplasmid), will be presented at the 2026 EORTC-NCI-AACR Symposium in Barcelona, Spain.

Key Highlights

  • Conference presentation: A Genprex-supported poster is scheduled for the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Wednesday, November 18, 2026, 12:00-6:00 p.m. CET, at CCIB, Barcelona, Spain (Abstract Number 108, Poster Board Number PB-108).
  • Primary resistance observed: Approximately 50% of 10 non-small cell lung cancer (NSCLC) cell lines and 50% of 12 patient-derived organoid models evaluated showed primary resistance to TUSC2 gene delivery, according to the filing.
  • TROP2 linked to resistance: Protein-expression analyses consistently identified low TROP2 expression as a marker associated with resistance across multiple preclinical models, the filing disclosed.
  • Clinical biopsy support: Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the association between TROP2 expression and treatment response.
  • TUSC2 prevalence: According to the filing, TUSC2 tumor suppressor protein expression is downregulated or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers.
  • Further research required: The filing noted that additional research and prospective clinical evaluation will be required to establish TROP2's predictive utility in patients receiving Reqorsa.

Genprex Discloses TROP2 Findings and Upcoming EORTC Poster Presentation

According to the Form 8-K filed with the SEC on November 4, 2026, Genprex, Inc. (NASDAQ:GNPX) issued a press release on that date announcing that research collaborators identified low TROP2 expression as consistently associated with resistance to Reqorsa across multiple preclinical models of NSCLC. The company disclosed that this finding was also supported by analysis of pretreatment tumor biopsies from patients enrolled in a clinical trial evaluating Reqorsa.

The filing described that experimental manipulation of TROP2 expression altered TUSC2-induced cancer cell death, "suggesting that TROP2-dependent signaling may play a role in therapeutic response," and that further research is underway to understand these context-dependent effects. The company also noted that Reqorsa's effects are mediated by inhibiting MAPK and mTOR signaling, inducing cell-cycle arrest and apoptosis, and activating antitumor immune responses. Previous studies, according to the filing, have shown that Reqorsa has antitumor activity, including in models resistant to targeted therapies and in immunotherapy-resistant KRAS/LKB1-mutant NSCLC.

The filing stated that the company believes the findings collectively identify TROP2 as a potential predictive biomarker for response to Reqorsa and suggest that modulating TROP2 signaling may be a novel strategy to enhance the therapeutic efficacy of Reqorsa in NSCLC. The poster, titled "TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment," falls under the topic "Drug Resistance and Modifiers." The filing indicated that the EORTC-NCI-AACR 2026 poster is expected to be available on Genprex's website following the presentation, subject to applicable conference disclosure requirements. The filing contains forward-looking statements that are the company's own and subject to its cautionary language, including risks detailed in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

Genprex filed an 8-K disclosing a press release announcing upcoming presentation of TROP2 biomarker research related to Reqorsa at the 2026 EORTC-NCI-AACR Symposium in Barcelona on November 18, 2026, including preclinical and supportive clinical findings on TROP2 expression and treatment resistance in NSCLC.